CA
SANA icon

CoreCap Advisors’s Sana Biotechnology SANA Stock Holding History

CoreCap Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-278
Closed -$467 – 3181
2025
Q1 		$467 Hold
278
– – ﹤0.01% 2707
2024
Q4 		$453 Buy
+278
New +$829 ﹤0.01% 2551

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CoreCap Advisors's SANA Position: Q2 2025 in Review

CoreCap Advisors sold out of Sana Biotechnology (SANA) in Q2 2025, closing a stake of 278 shares — an estimated $467 sold.

CoreCap Advisors first reported a position in SANA in Q4 2024 and held it in 2 quarters. The position peaked at $467 in Q1 2025. 155 funds tracked by Wall St. Rank hold SANA as of Q2 2025.

  • CoreCap Advisors reported no remaining Sana Biotechnology position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 278 Sana Biotechnology shares in Q2 2025, an estimated $467.
  • CoreCap Advisors first reported a position in Sana Biotechnology in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Sana Biotechnology position peaked at $467 in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.